Click here to go to the previous page
Case Presentations in Hodgkin's Disease and Lymphoma
Program Code:
EDU311
Date:
Tuesday, November 3, 2009
SPEAKER(S):
Peter Mauch, MD, FASTRO, Brigham & Women's Hospital
Leo Gordon,
M.D., Professor,
Northwestern University, Feinberg School of Medicine
My laboratory is interested in translational research in lymphoma. We are investigating novel signaling pathways in lymphoma, using cell lines and animal model systems. Our research is currently focused on the biology of reactive oxygen species signaling pathways, and active investigations include: 1) the biology of arsenicals in lymphoma cell death pathways, in collaboration with Dr. Leon Platanias, Dr. Jane Winter, Dr. Andrew Evens and Dr. Tom OHalloran, all from Northwestern; 2) the biology of the lactone diterpenoids in lymphoma; 3) the development of all trans retinoic acid (ATRA) loaded nanodisks as a drug delivery vehicle in mantle cell lymphoma (MCL), in collaboration with investigators from the Childrens Hospital Research Institute (CHORI) in Oakland, CA.; 4) the study of hypoxia inducible factor (HIF) in lymphoma, in collaboration with Dr Paul Schumacker and Dr Andrew Evens. Clinical research interests include the study of novel immune stimulatory strategies following stem cell transplant in lymphoma and new approaches to the use of radioimmunotherapy (RIT) in lymphoma. Clinical research studies are carried out through the Northwestern University Lymphoma Program and through national co-operative groups such as the Eastern Co-operative Oncology Group (ECOG).
|
Joachim Yahalom, Professor, Memorial Sloan-Kettering Cancer Center
Dr. Richard Hopp's research interests include irradiation immunosuppression; total body irradiation;, psychosocial effects of cancer treatment; treatment of lymphoma; and mycosis fungoides.
|
Mary Gospodarowicz, Professor, Princess Margaret Hospital